University of Kentucky · PharmacologyPulmonary Fibrosis Research Unit
Christine Fillmore Brainson · Lexington, Kentucky
Research Focus
Dr. Christine Fillmore Brainson's lab focuses on understanding and treating pulmonary fibrosis, a serious lung disease characterized by the buildup of scar tissue that impairs breathing. The lab is exploring how epigenetic therapies, particularly involving the EZH2 enzyme, can help revert or prevent this fibrosis. Their research combines cell culture techniques with animal models to innovate possible treatments that target cellular behavior and gene expression in the lungs.
pulmonary fibrosisepigenetic therapyEZH2lung functioncellular reprogramming
Research Aims
4AIM 01Investigate whether EZH2 inhibition can prevent abnormal lung cell transformations.
AIM 02Assess the effects of EZH2 inhibition on inflammatory markers in lung cells.
AIM 03Characterize lung cell populations in fibrotic models using histology and flow cytometry.
AIM 04Evaluate the potential of an FDA-approved EZH2 inhibitor as a treatment for pulmonary fibrosis.
Skills the Lab Values
cell culturein vivo modelsflow cytometryscRNA-seqCrispr gene editing
Output against the department
Publications134bottom 38% of dept.288th of 462
this lab
most publishedleast published
Citations956bottom 4% of dept.445th of 462
this lab
most citedleast cited
Career totals from OpenAlex, compared against labs that share a department. A department spans everything from one paper to tens of thousands, so bar heights are on a log scale — otherwise the largest lab would flatten every other bar to a line.